Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This retrospective database study analyzed resource utilization and costs associated with
sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy
among adults with a diagnosis of diabetes who were continuously enrolled in a large US
healthcare plan.